SAUDI PHARMACEUTICAL INDUSTRIES AND MEDICAL APPLIANCES CORPORATION

Northwest Biotherapeutics Signs MOU with SPIMACO to Bring DCVax-L Personalized Immunotherapy for Glioblastoma to Saudi Arabia

- Northwest Biotherapeutics and SPIMACO entered a non-binding MOU to bring DCVax-L, a personalized dendritic cell vaccine for glioblastoma, to Saudi Arabia. - The collaboration covers regulatory approval through the Saudi FDA, commercialization, supply, and eventual localized manufacturing under a revenue-sharing model. - SPIMACO, a leading pharma company across 21 MENA markets, will lead marketing, sales, and distribution while NWBio retains all intellectual property rights. - The partnership aligns with Saudi Arabia's Vision 2030 plan to establish the Kingdom as a global hub for life sciences and biotechnology.